We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

TPCS:NASDAQTechPrecision Corporation Analysis

Data as of 2026-05-27 - not real-time

$3.99

Latest Price

8/10Risk

Risk Level: High

Executive Summary

TechPrecision Corp. (TPCS) is trading at $3.99, just above its identified support of $3.75 and well below its 200‑day SMA of $4.51, indicating long‑term weakness despite a short‑term price above the 50‑day SMA ($3.72). The RSI sits at 52, suggesting a neutral momentum, while the MACD histogram is negative and the MACD line remains below its signal line, flagging bearish technical pressure. Volatility is elevated at roughly 51% over the past 30 days, and the market sentiment is in an "Extreme Greed" phase, which may be inflating the price temporarily. Fundamentally, the company reports a 6.9% revenue decline, negative operating (-19%) and profit margins (-3.4%), and a trailing EPS of –$0.12, yet it projects a forward EPS of $1.58, implying an expected earnings turnaround. The balance sheet is strained with $10.5 M of debt versus a mere $70 k in cash, yielding a debt‑to‑equity ratio of 132 and negative free cash flow of –$1.83 M. Valuation metrics such as a forward P/E of 2.5 versus an industry average of 30 appear cheap, but a price‑to‑book of 5× and high leverage temper enthusiasm.

Market Outlook

Short Term

< 1 year
Cautious
Model confidence: 6/10

Key Factors

  • Price near technical support with bearish MACD
  • High 30‑day volatility (~51%)
  • Negative earnings and cash flow

Medium Term

1–3 years
Neutral
Model confidence: 5/10

Key Factors

  • Forward EPS forecast suggests potential earnings recovery
  • Low beta (0.68) indicating limited market sensitivity
  • Continued debt burden and limited liquidity

Long Term

> 3 years
Positive
Model confidence: 7/10

Key Factors

  • Defense and aerospace contract exposure provides stable revenue tailwinds
  • Forward P/E of 2.5 versus industry average of 30 indicates deep value
  • Potential turnaround if operating margins improve

Key Metrics & Analysis

Financial Health

Revenue Growth-6.90%
Profit Margin-3.43%
P/E Ratio2.5
ROE-14.09%
ROA-0.17%
Debt/Equity131.72
P/B Ratio5.0
Op. Cash Flow$143.0K
Free Cash Flow$-1831250
Industry P/E30.1

Technical Analysis

TrendNeutral
RSI52.1
Support$3.75
Resistance$4.50
MA 20$4.04
MA 50$3.72
MA 200$4.51
MACDBearish
VolumeStable
Fear & Greed Index92.34

Valuation

GradeUndervalued
TypeBlend

Risk Assessment

Beta0.68
Volatility50.90%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.